Terns Pharmaceuticals Statistics
Total Valuation
TERN has a market cap or net worth of $262.89 million. The enterprise value is -$66.65 million.
Important Dates
The last earnings date was Thursday, May 8, 2025, before market open.
| Earnings Date | May 8, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
TERN has 87.34 million shares outstanding. The number of shares has increased by 15.69% in one year.
| Current Share Class | 87.34M |
| Shares Outstanding | 87.34M |
| Shares Change (YoY) | +15.69% |
| Shares Change (QoQ) | +0.26% |
| Owned by Insiders (%) | 0.75% |
| Owned by Institutions (%) | 69.01% |
| Float | 53.75M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.81 |
| P/TBV Ratio | 0.82 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 30.89, with a Debt / Equity ratio of 0.00.
| Current Ratio | 30.89 |
| Quick Ratio | 30.57 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -32.12% and return on invested capital (ROIC) is -23.00%.
| Return on Equity (ROE) | -32.12% |
| Return on Assets (ROA) | -22.15% |
| Return on Invested Capital (ROIC) | -23.00% |
| Return on Capital Employed (ROCE) | -31.63% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.53M |
| Employee Count | 59 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, TERN has paid $251,000 in taxes.
| Income Tax | 251,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -45.86% in the last 52 weeks. The beta is -0.17, so TERN's price volatility has been lower than the market average.
| Beta (5Y) | -0.17 |
| 52-Week Price Change | -45.86% |
| 50-Day Moving Average | 2.96 |
| 200-Day Moving Average | 5.72 |
| Relative Strength Index (RSI) | 50.99 |
| Average Volume (20 Days) | 1,035,979 |
Short Selling Information
The latest short interest is 5.42 million, so 6.20% of the outstanding shares have been sold short.
| Short Interest | 5.42M |
| Short Previous Month | 5.58M |
| Short % of Shares Out | 6.20% |
| Short % of Float | 10.07% |
| Short Ratio (days to cover) | 4.07 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -103.85M |
| Pretax Income | -95.63M |
| Net Income | -90.39M |
| EBITDA | -103.56M |
| EBIT | -103.85M |
| Earnings Per Share (EPS) | -$1.08 |
Full Income StatementBalance Sheet
The company has $334.26 million in cash and $1.24 million in debt, giving a net cash position of $333.03 million or $3.81 per share.
| Cash & Cash Equivalents | 334.26M |
| Total Debt | 1.24M |
| Net Cash | 333.03M |
| Net Cash Per Share | $3.81 |
| Equity (Book Value) | 326.04M |
| Book Value Per Share | 3.73 |
| Working Capital | 326.81M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$71.66 million and capital expenditures -$13,000, giving a free cash flow of -$71.67 million.
| Operating Cash Flow | -71.66M |
| Capital Expenditures | -13,000 |
| Free Cash Flow | -71.67M |
| FCF Per Share | -$0.82 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |